Full-Time

Obesity Intelligence & Analytics Senior Director

Global Insights

Updated on 9/10/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$216.6k - $293.1k/yr

+ Annual bonus + Stock-based long-term incentives

Thousand Oaks, CA, USA

Hybrid

Three days on campus per week required.

Bachelor's, Master's, PhD

Category
Business & Strategy (1)
Required Skills
Forecasting
Data Analysis

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Doctorate degree and 5 years of experience in market research, commercial insights, analytics, competitive intelligence, forecasting, strategy, marketing, or a related discipline; or a Master's degree and 9 years of experience; or a Bachelor's degree and 11 years of experience.
  • At least 5 years of managerial experience directly managing people and/or leadership experience directing teams, major programs, complex projects, or the allocation of significant resources.
Responsibilities
  • Serve as the senior insights partner for the Global Obesity Program and develop trusted relationships with global commercial leaders and cross-functional stakeholders.
  • Establish and lead an integrated global insights agenda aligned with therapeutic area priorities, asset strategies, clinical development milestones, commercialization needs, and internal governance decisions.
  • Lead the design and execution of primary market research across the product lifecycle, including early asset assessment, clinical development, target product profile optimization, positioning, segmentation, launch planning, lifecycle management, and indication expansion.
  • Integrate primary research, secondary analytics, forecasting, competitive intelligence, advisory boards, real-world evidence, and internal expertise to develop a cohesive understanding of the market and its implications.
  • Partner with Forecasting, Analytics, Competitive Intelligence, Value & Access, Medical, and Clinical Development teams to translate insights into aligned assumptions, scenarios, strategic choices, and business recommendations.
  • Provide insight leadership for obesity therapeutic area strategy, including market development, patient and healthcare professional needs, treatment pathways, competitive evolution, portfolio opportunities, and potential future standards of care.
  • Develop business cases, scenario analyses, strategic workshops, and senior-level narratives to support portfolio decisions, clinical development plans, investment prioritization, lifecycle strategy, and governance discussions.
  • Translate complex findings into clear implications and recommendations for senior leadership, governance committees, and executive-level audiences.
  • Act as an objective strategic thought partner and constructive challenger by identifying evidence gaps, testing assumptions, reconciling conflicting information, and introducing alternative perspectives.
  • Lead stakeholder alignment around business questions, learning priorities, budgets, work plans, methodologies, and decision timelines across multiple assets and workstreams.
  • Identify and develop innovative insight-generation approaches, data sources, analytic methods, and external partnerships that strengthen understanding of the obesity market.
  • Select and manage research and consulting partners, ensuring that external work meets expectations for strategic relevance, methodological rigor, quality, timeliness, and budget.
  • Lead and develop direct reports and cross-functional project teams while personally leading select high-priority initiatives.
  • Ensure that projects comply with applicable policies, standard operating procedures, legal and regulatory requirements, and service-level expectations.
Desired Qualifications
  • Demonstrated ability to serve as a strategic advisor to senior commercial, medical, clinical, and cross-functional leaders.
  • Strong understanding of global drug development, commercialization, portfolio strategy, and the broader healthcare environment, including patients, healthcare professionals, payers, policymakers, and health systems.
  • Experience supporting early- and late-stage assets, therapeutic area strategy, product launches, lifecycle planning, or portfolio investment decisions.
  • Deep experience leading primary market research and integrating research findings with secondary data, analytics, competitive intelligence, and forecasting.
  • Strong business acumen, strategic and critical thinking, and ability to identify implications of incomplete, complex, or conflicting information.
  • Ability to frame ambiguous business issues, establish hypotheses and learning priorities, and translate evidence into actionable strategic recommendations.
  • Demonstrated ability to influence decisions without direct authority and align stakeholders with different functional perspectives, priorities, and incentives.
  • Experience operating across global and local organizations and balancing therapeutic area, asset, functional, and geographic stakeholder needs.
  • Executive communication and storytelling skills, including the ability to simplify complex concepts and articulate implications, choices, risks, and recommendations.
  • Ability to manage multiple high-priority initiatives simultaneously while maintaining strategic focus, analytical rigor, and execution.
  • Demonstrated people leadership capabilities, including attracting, developing, coaching, and retaining high-performing talent.
  • Experience within obesity, cardiometabolic disease, or another complex and rapidly evolving therapeutic area.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 10% to $10.1 billion, and guidance increased to $38.2 billion-$39.4 billion.
  • Repatha sales jumped 37% to $953 million in Q2 2026, with U.S. prescriptions up 50%.
  • MariTide advanced through multiple Phase 3 studies in 2026, supporting a 2027 obesity catalyst.

What critics are saying

  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy cash cow.
  • FDA proposed withdrawing Tavneos in April 2026, signaling regulatory risk from integrity and efficacy issues.
  • Olpasiran now faces Novartis pelacarsen failure scrutiny; a negative 2028 OCEAN(a) readout would crush Lp(a) upside.

What makes Amgen unique

  • Repatha, Evenity, and Uplizna diversify Amgen beyond one blockbuster, per August 2026 sales.
  • MariTide targets quarterly or eight-week dosing, unlike Lilly and Novo Nordisk weekly injections.
  • Amgen’s 2027 Hyderabad Science and Innovation Center expands AI-enabled drug discovery globally.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 10th, 2026
Amgen trades at 17x 2026 earnings, but forecast margin expansion assumes MariTide success

Amgen trades at $393 per share, representing a trailing multiple of 23.3 times adjusted earnings. The biotech faces declining sales from Prolia and XGEVA, down 33% year-over-year to $1.1 billion in Q2 2026, due to biosimilar competition. Six key growth medicines grew 26% year-over-year, accounting for nearly 70% of Q2 product sales. Analysts forecast the forward multiple at 17.0 times for fiscal 2026 and 16.1 times for 2027. However, consensus assumes expanding profit margins whilst Amgen increases spending. Non-GAAP research spending is set to grow in high single digits for 2026, funding nine Phase III trials for MariTide, its obesity treatment candidate. Management warned of meaningful operating expense increases in Q3 2026. The valuation depends on margin expansion materialising during this investment phase.

Yahoo Finance
Sep 7th, 2026
Amgen's $437 olpasiran bet faces higher bar after Novartis Lp(a) drug fails Phase 3 trial

Amgen faces heightened scrutiny for its experimental heart drug olpasiran after rival Novartis's pelacarsen failed to reduce major cardiovascular events in a Phase 3 trial, despite successfully lowering lipoprotein(a) levels. The setback demonstrates that improving laboratory biomarkers may not translate to better patient outcomes. Amgen's OCEAN(a) outcomes study has enrolled 7,297 participants and is tracking heart-related deaths and procedures over roughly five years. While olpasiran uses a different design and may target different patients, pelacarsen's failure removes assumptions about the commercial value of lowering Lp(a). Amgen's shares traded at $437.23, sitting 19.54% above its estimated fair value of $365.76. The company reported $10.1 billion in second-quarter revenue and $3.5 billion in free cash flow.

Yahoo Finance
Sep 1st, 2026
Amgen's Repatha hits $953M in Q2 sales, up 37% as Cramer calls it "biggest market of all time

Jim Cramer highlighted Amgen's cholesterol drug Repatha as a key driver behind the company's 31% year-to-date rally, calling it an overlooked catalyst by Wall Street. The injectable treatment, administered every two weeks, reduces death risk by 20% in patients at high risk for heart attack or stroke. Repatha generated $953 million in second-quarter sales, up 37% year-over-year. US new prescriptions surged over 50%, split evenly between cardiologist use and primary-care adoption for high-risk patients. Cramer noted the drug works against diabetes and high cholesterol, though insurance reimbursement has posed challenges. Amgen trades at a forward PE of 19, compared to Eli Lilly's 32, whilst outperforming Lilly's 10% gain this year. Repatha is one of six growth drivers representing nearly 70% of Amgen's product sales. The company raised full-year revenue guidance to $38.2-$39.4 billion.

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.